Tempus Reports Third Quarter 2026 Results
Stocks in this Quantisnow insightTechnology · Health Care
Quantisnow AI summary
Q3 revenue $411.5M, up 23%; FY26 revenue guidance raised to $1.60-1.605B; Adj. EBITDA $25.6M vs $1.5M y/y.
Historical context for TEM
Across the 28 sessions after earlier TEM headlines, the stock closed higher 10 times and lower 18 times, with a median move of 1.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TEM | SPY |
|---|---|---|---|
| Oct 26, 2026 | Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling | -0.7% | +0.7% |
| Oct 19, 2026 | Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC | -0.6% | +0.4% |
| Oct 16, 2026 | Tempus to Report Third Quarter 2026 Financial Results on November 2 | -9.0% | -1.1% |
| Oct 13, 2026 | Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases | +0.3% | -0.0% |
| Oct 7, 2026 | Tempus Announces Multi-Year Collaboration with Moderna and Merck | -2.3% | -0.2% |
| Oct 1, 2026 | Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026 | -6.6% | +0.2% |
Quantisnow market dataNASDAQ
TEM
Tempus AI Inc.
- Market cap
- 30-day
- Sector
- Technology
- Industry
- Computer Software: Programming Data Processing
- Listed since
- 2024
Get push alerts for TEM
Full TEM profile on Quantisnow Follow TEM and get a push notification the moment its next story breaks.